Company profile
FOGHORN THERAPEUTICS INC.
NASDAQ:FHTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CAMIBIRSTAT | phase1 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04891757 | phase1 | active_not_recruiting | 2021-06-14 | 2025-09-01 | Foghorn Therapeutics Inc. | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies |
| NCT04879017 | phase1 | terminated | 2021-05-11 | 2023-11-30 | Foghorn Therapeutics Inc. | FHD-286 in Subjects With Metastatic Uveal Melanoma |
| NCT04965753 | phase1 | terminated | 2021-08-17 | 2023-12-04 | Foghorn Therapeutics Inc. | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors |
FDA applications (0)
No records yet.